Recap: Candel Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Candel Therapeutics (NASDAQ:CADL) reported Q4 earnings with an EPS of $-0.38, missing estimates by -138.0% compared to the expected $-0.16. Revenue decreased by $31 thousand from the same period last year. Despite missing EPS estimates last quarter followed by a 4.0% share price increase the next day, this quarter's performance may concern investors.

March 28, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Candel Therapeutics reported a significant miss in Q4 earnings with an EPS of $-0.38, far below the expected $-0.16, and a decrease in revenue by $31 thousand from the previous year.
The significant miss in earnings expectations and the decrease in revenue compared to the previous year are likely to negatively impact investor sentiment and potentially lead to a short-term decrease in CADL's stock price. Historical context shows that despite a miss in EPS last quarter, the stock price increased by 4.0% the following day, indicating that market reactions can be unpredictable. However, the magnitude of this miss and revenue decline suggests a more cautious short-term outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100